Evidence map›Paper›PMID 23045593›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.

Paul Greaves, Andrew Clear, Rita Coutinho, Andrew Wilson, Janet Matthews, Andrew Owen, Milensu Shanyinde, T Andrew Lister, Maria Calaminici, John G Gribben

Erratum issuedAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Macrophages and angiogenesis in human lymphomas.Clinical and experimental medicine · 2024
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Paul GreavesBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom. p.greaves@qmul.ac.uk
Andrew Clear
Rita Coutinho
Andrew Wilson
Janet Matthews
Andrew Owen
Milensu Shanyinde
T Andrew Lister
Maria Calaminici
John G Gribben
Queen Mary University of London · GB

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RASSENTI, LAURA Z · 2000 to 2016
$59.5M
Cancer Research UKNCI NIH HHS P01 CA081534
6 · The paper itself

Abstract

purposeThe immune microenvironment is key to the pathophysiology of classical Hodgkin lymphoma (CHL). Twenty percent of patients experience failure of their initial treatment, and others receive excessively toxic treatment. Prognostic scores and biomarkers have yet to influence outcomes significantly. Previous biomarker studies have been limited by the extent of tissue analyzed, statistical inconsistencies, and failure to validate findings. We aimed to overcome these limitations by validating recently identified microenvironment biomarkers (CD68, FOXP3, and CD20) in a new patient cohort with a greater extent of tissue and by using rigorous statistical methodology. PATIENTS AND

methodsDiagnostic tissue from 122 patients with CHL was microarrayed and stained, and positive cells were counted across 10 to 20 high-powered fields per patient by using an automated system. Two statistical analyses were performed: a categorical analysis with test/validation set-defined cut points and Kaplan-Meier estimated outcome measures of 5-year overall survival (OS), disease-specific survival (DSS), and freedom from first-line treatment failure (FFTF) and an independent multivariate analysis of absolute uncategorized counts.

resultsIncreased CD20 expression confers superior OS. Increased FOXP3 expression confers superior OS, and increased CD68 confers inferior FFTF and OS. FOXP3 varies independently of CD68 expression and retains significance when analyzed as a continuous variable in multivariate analysis. A simple score combining FOXP3 and CD68 discriminates three groups: FFTF 93%, 62%, and 47% (P < .001), DSS 93%, 82%, and 63% (P = .03), and OS 93%, 82%, and 59% (P = .002).

conclusionWe have independently validated CD68, FOXP3, and CD20 as prognostic biomarkers in CHL, and we demonstrate, to the best of our knowledge for the first time, that combining FOXP3 and CD68 may further improve prognostic stratification.

Indexed as

Antigens, CDAntigens, CD20Antigens, Differentiation, MyelomonocyticBiomarkers, TumorCD68 MoleculeFemaleForkhead Transcription FactorsHodgkin DiseaseHumansMaleMiddle AgedPrognosisSurvival AnalysisTreatment OutcomeTumor MicroenvironmentAntigens, CDAntigens, CD20Antigens, Differentiation, MyelomonocyticBiomarkers, TumorCD68 antigen, humanCD68 MoleculeForkhead Transcription FactorsFOXP3 protein, human

Identifiers

PMID23045593
PMCPMC5321049
OpenAlexW2101039041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.